Current Status of Stroke Thrombolysis in the Mission Thrombectomy 2020+ Caribbean Region

Author:

Gordon Perue Gillian1ORCID,Segura Esmeralda2,Crandon Domini1,Gayle Francene3,Charles Jude1,Joseph Nycole4,Saint Croix Garly5,Then Ryna6,Inoa Violiza7,

Affiliation:

1. Department of Neurology/Jackson Health SystemUniversity of Miami University of Miami Miller School of MedicineMiami FL USA

2. University of Miami Miller School of Medicine Miami Miami FL

3. King Edward Memorial Hospital Paget Bermuda

4. Ballad Health Department of Neurology Greeneville TN

5. Montefiore Medical Center/Albert Einstein College of Medicine New York New York NY

6. Cooper Medical School of Rowan University Camden NJ

7. University of Tennessee Health Science Center, Memphis Tennessee Semmes‐Murphey Clinic Memphis TN

Abstract

Background Low‐ to middle‐income countries have limited access to thrombolytic therapy. To our knowledge, there is no validated tool available to objectively measure access to thrombolytic agents or barriers to routine clinical use. Methods We developed the 17‐item tissue plasminogen activator Spot Check tool to assess usage of acute stroke thrombolysis regarding local experience, financial constraints, and perceived barriers to care; evaluating the current state of clinical practices in the Mission Thrombectomy 2020+ Caribbean region. The survey was disseminated via an online link, and the information was collected and analyzed via SPSS. Results The tool was validated by 3 international experts with an Average Content Validity Index of 1 and a Universal Agreement Index of 1 across 3 domains: local experience, financial constraints, and barriers to usage. The participant survey response rate was 64%, representing 15 of 44 Mission Thrombectomy 2020+ Caribbean countries. There was limited or no access to thrombolytic agents in 40% of countries surveyed. Among cases treated with thrombolytics, 43% of patients had to pay out of pocket before treatment was provided, and l<10% were covered by insurance/government. Among 51% of countries surveyed, no acute thrombolytic treatment was provided for acute stroke in the 2021 calendar year. Only 1 center treated >100 cases per year. Most respondents (88%) agreed there were barriers to acute stroke thrombolysis in the region. The tissue plasminogen activator Spot Check tool was able to identify barriers impacting the number of cases per year, including absence of stroke protocol ( P <0.001), upfront cost of alteplase ( P = 0.003), restricted the amount of thrombolytics ( P = 0.002), neurology intensive care unit or stroke unit monitoring of patients following thrombolytics ( P = 0.017), cost of thrombolytic agents to the hospital ( P = 0.042), and access to computed tomography scan ( P = 0.03). Conclusion This survey brings light to an enormous disparity in the care of stroke patients around the world, specifically in the Mission Thrombectomy 2020+ Caribbean region.

Publisher

Ovid Technologies (Wolters Kluwer Health)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3